Shopping Cart 0
Cart Subtotal
USD 0

Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.

Teijin Ltd (3401)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Teijin Pharma Enters into Discovery Agreement with PeptiDream 12

Teijin Enters into Distribution Agreement with Taisho Pharma 13

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16

NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17

Licensing Agreements 18

Teijin Enters into Licensing Agreement with Merz Pharma 18

Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19

Teijin Enters into Licensing Agreement with Radius Health 20

Merck Enters into Licensing Agreement with Teijin Pharma 21

Amgen Enters into Licensing Agreement with Teijin Pharma 22

Teijin Pharma Enters into Licensing Agreement with Versartis 23

Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24

Debt Offering 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26

Acquisition 27

Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27

Teijin Ltd-Key Competitors 28

Teijin Ltd-Key Employees 29

Teijin Ltd-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 33

Recent Developments 34

Financial Announcements 34

May 09, 2018: Teijin: Consolidated Financial Statements Summary For the year ended March 31, 2018 34

May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37

Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teijin Pharma Enters into Discovery Agreement with PeptiDream 12

Teijin Enters into Distribution Agreement with Taisho Pharma 13

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16

NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17

Teijin Enters into Licensing Agreement with Merz Pharma 18

Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19

Teijin Enters into Licensing Agreement with Radius Health 20

Merck Enters into Licensing Agreement with Teijin Pharma 21

Amgen Enters into Licensing Agreement with Teijin Pharma 22

Teijin Pharma Enters into Licensing Agreement with Versartis 23

Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26

Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27

Teijin Ltd, Key Competitors 28

Teijin Ltd, Key Employees 29

Teijin Ltd, Other Locations 31

Teijin Ltd, Subsidiaries 31

Teijin Ltd, Joint Venture 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Teijin Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.

Teijin Ltd (3401)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Teijin Pharma Enters into Discovery Agreement with PeptiDream 12

Teijin Enters into Distribution Agreement with Taisho Pharma 13

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16

NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17

Licensing Agreements 18

Teijin Enters into Licensing Agreement with Merz Pharma 18

Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19

Teijin Enters into Licensing Agreement with Radius Health 20

Merck Enters into Licensing Agreement with Teijin Pharma 21

Amgen Enters into Licensing Agreement with Teijin Pharma 22

Teijin Pharma Enters into Licensing Agreement with Versartis 23

Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24

Debt Offering 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26

Acquisition 27

Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27

Teijin Ltd-Key Competitors 28

Teijin Ltd-Key Employees 29

Teijin Ltd-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 33

Recent Developments 34

Financial Announcements 34

May 09, 2018: Teijin: Consolidated Financial Statements Summary For the year ended March 31, 2018 34

May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37

Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Teijin Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teijin Pharma Enters into Discovery Agreement with PeptiDream 12

Teijin Enters into Distribution Agreement with Taisho Pharma 13

Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16

NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17

Teijin Enters into Licensing Agreement with Merz Pharma 18

Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19

Teijin Enters into Licensing Agreement with Radius Health 20

Merck Enters into Licensing Agreement with Teijin Pharma 21

Amgen Enters into Licensing Agreement with Teijin Pharma 22

Teijin Pharma Enters into Licensing Agreement with Versartis 23

Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25

Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26

Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27

Teijin Ltd, Key Competitors 28

Teijin Ltd, Key Employees 29

Teijin Ltd, Other Locations 31

Teijin Ltd, Subsidiaries 31

Teijin Ltd, Joint Venture 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Teijin Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.